Orthocell Ltd
ASX:OCC

Watchlist Manager
Orthocell Ltd Logo
Orthocell Ltd
ASX:OCC
Watchlist
Price: 0.615 AUD 0.82% Market Closed
Market Cap: 147.1m AUD
Have any thoughts about
Orthocell Ltd?
Write Note

EV/EBIT
Enterprise Value to EBIT

-12.4
Current
-7.5
Median
4.1
Industry
Lower than median
Lower than industry value

Enterprise Value to EBIT (EV/EBIT) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s earnings before interest and taxes (EBIT). Considered one of the most frequently used multiples for comparisons among companies, the EV/EBIT multiple relies on operating income as the core driver of valuation.

EV/EBIT
-12.4
=
Enterprise Value
127m AUD
/
EBIT
-10.2m AUD
All Countries
Close
Market Cap EV/EBIT
AU
Orthocell Ltd
ASX:OCC
147.1m AUD -12.4
FR
Pharnext SCA
OTC:PNEXF
6T USD -217 288.5
US
Abbvie Inc
NYSE:ABBV
312.7B USD 23.6
US
Amgen Inc
NASDAQ:AMGN
158.3B USD 33.1
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
115.9B USD 25.2
US
Gilead Sciences Inc
NASDAQ:GILD
112.4B USD 9.9
US
Epizyme Inc
F:EPE
94.1B EUR -500.3
AU
CSL Ltd
ASX:CSL
133.6B AUD 25.3
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
82.6B USD 18
US
Seagen Inc
F:SGT
39.3B EUR -53
NL
argenx SE
XBRU:ARGX
34.5B EUR -76.2
EBIT Growth
AU
Orthocell Ltd
ASX:OCC
Average EV/EBIT: 22.5
Negative Multiple: -12.4
N/A
FR
Pharnext SCA
OTC:PNEXF
Negative Multiple: -217 288.5 N/A
US
Abbvie Inc
NYSE:ABBV
23.6
88%
US
Amgen Inc
NASDAQ:AMGN
33.1
93%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
25.2
44%
US
Gilead Sciences Inc
NASDAQ:GILD
9.9
29%
US
E
Epizyme Inc
F:EPE
Negative Multiple: -500.3 N/A
AU
CSL Ltd
ASX:CSL
25.3
55%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
18
54%
US
S
Seagen Inc
F:SGT
Negative Multiple: -53 N/A
NL
argenx SE
XBRU:ARGX
Negative Multiple: -76.2 N/A

EV/EBIT Forward Multiples

Forward EV/EBIT multiple is a version of the EV/EBIT ratio that uses forecasted EBIT for the EV/EBIT calculation. 1-Year, 2-Years, and 3-Years forwards use EBIT forecasts for 1, 2, and 3 years ahead, respectively.

1-Year Forward
EV/EBIT
-15.2
2-Years Forward
EV/EBIT
-370.9
3-Years Forward
EV/EBIT
N/A

See Also

Discover More